Best Neurology Companies in British Columbia, Canada
The 33 best Neurology companies in British Columbia, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Neuromed Pharmaceuticals.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in British Columbia
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Neuromed Pharmaceuticals Provider of calcium channel blockers for pain treatment | $126M | 230 mo ago | Deadpooled | Peter Beltran CEO | — | 102 patents Novel calcium channel blocker compounds for cardiovascular and neurological therapeutics | — |
| 2 | Xenon Pharmaceuticals Developer of small molecule drugs against rare channelopathies | $86M | 241 mo ago | Public | Simon Pimstone CEO | 19 | 1,483 patents Novel heteroaryl amine drug candidates for CNS disorders, especially epilepsy treatment | — |
| 3 | MSI Methylation Sciences Developer of small molecule therapies for major depressive disorder (MDD) | $48M | 120 mo ago | Deadpooled | — | 11 | 14 patents Enhanced bioavailable SAMe formulations for folate deficiency treatment | — |
| 4 | AlphaCognition Developer of therapeutics to treat neurological disease | $26M | 25 mo ago | Public | Michael Mcfadden CEO | 4 | — | — |
| 5 | NervGen Developer of therapeutics for the treatment of nerve damage | $22M | 48 mo ago | Public | Harold Punnett Director | 11 | — | — |
| 6 | Evasc Medical Endovascular repair of cerebral aneurysms | $20M | — | Early Stage | — | 23 | — | — |
| 7 | Bionxt Developer of drug formulations and delivery systems for various diseases 37News top 36%Funding top 38%Partners top 40%Patents top 46% All 11 signals ▾Newstop 36% Fundingtop 38% Partnerstop 40% Patentstop 46% Growthtop 47% Talenttop 49% Moatbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 39% Globalbottom 38% News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $13M | 20 mo ago | Public | Hugh Rogers CEO | 25 | 7 patents Patents concentrated in health & consumer products | — |
| 8 | Tryp Therapeutics Developer of therapeutic solutions for treating neuropsychiatric disorders & pain | $4M | 36 mo ago | Public | — | 11 | 23 patents Psychedelic drug formulations and therapeutic methods for eating disorders and fibromyalgia | — |
| 9 | Clairvoyant Therapeutics Manufacturer of psychedelic therapy drug for addiction | $2M | 59 mo ago | Acquired | — | 11 | — | — |
| 10 | Mynd Manufacturer of drugs for neurological disorders | $2M | 59 mo ago | Public | Wilfred Jefferies Co-Founder & Chief Science Officer | — | — | — |
| 11 | Aequus Pharma Developer of pharmaceutical products for the treatment of neurology and psychiatric diseases | $2M | 74 mo ago | Public | — | 18 | — | — |
| 12 | ImStar Therapeutics Small molecule therapeutics for Amyotrophic Lateral Sclerosis (ALS) and neurodegenerative diseases | $2M | 124 mo ago | Deadpooled | Daniel Wattier Founder & CEO | 4 | 17 patents Therapeutic withanolide compounds for treating neurodegenerative diseases | — |
| 13 | Health Tech Connex Brain wave monitoring devices | $2M | 73 mo ago | Seed | — | 48 | — | — |
| 14 | Lobe Sciences Developer of small-molecule-based therapeutic solutions for the treatment of neurological disorders 50Growth top 15%News top 25%Moat top 32%Patents top 35% All 10 signals ▾Growthtop 15% Newstop 25% Moattop 32% Patentstop 35% Innovationtop 41% Talenttop 44% Fundingtop 47% Techbottom 46% Globalbottom 33% Marketbottom 25% Growth: Fresh capital in last 24 mo News: 8 BI events in 12 mo (of 14 tracked, 3 types) · +700% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $942K | 6 mo ago | Public | Tom Baird CEO | — | 25 patents Stable psilocin salt formulations for therapeutic psychedelic applications | — |
| 15 | Allon Therapeutics Develops therapies for the central nervous system | $500K | 173 mo ago | Acqui-Hired | — | 8 | 24 patents Peptide mimetic therapeutics for neuroprotection and treatment of neurodegenerative disorders | — |
| 16 | NeonMind Developer of psychedelic drugs for the treatment of obesity | $394K | 55 mo ago | Public | Penny White Founder | 3 | — | — |
| 17 | Champignon Brands Developer of psychedelic drug formulations for mental health. | $228K | 77 mo ago | Public | Gareth Birdsall CEO | — | — | — |
| 18 | Nirvana Life Science Developer of therapeutics for the treatment of opioid addiction | $150K | 52 mo ago | Public | Bruce Clark CEO | — | — | — |
| 19 | Sustained Therapeutics Provider of drug delivery platform for the treatment of chronic pain | $100K | 49 mo ago | Seed | Martin Gleave Co-Founder | — | — | — |
Top 12 Neurology companies in British Columbia
#1
Public · Vancouver, British Columbia · founded 2018$942.3Kraised▾
Developer of small-molecule-based therapeutic solutions for the treatment of neurological disorders. The company has developed psilocybin and N-Acetylcysteine drug for the treatment of mild traumatic brain injury & stress disorder. It has also developed devices to treat brain traumas.
- Apr 2026Post IPO$693.4K
- Jul 2025Post IPO$248.8K
- Dec 2020Post IPO—
#2
Public · Vancouver, British Columbia · founded 2018 · 25 employees$12.6Mraised▾
Developer of drug formulations and delivery systems for various diseases. The company focuses on developing precision transdermal and oral dissolvable drug delivery formulations, rapid, infectious disease, and oral health screening tests, and clinical evaluation of active pharmaceutical ingredients for neurological applications. The company's product include Vektor a drug formulation for efficient and affordable delivery of approved neurological medications.
- Feb 2025Post IPO$1.7M
- Jan 2025Post IPO$138.9K
- Jan 2025Post IPO$620.1K
- Jan 2025Post IPO$288.8K
#3
Public · Vancouver, British Columbia · founded 2000 · 4 employees$25.8Mraised▾
AlphaCognition is a developer of therapeutics to treat diseases of the brain and spinal cord. The therapeutics developed are a patented new chemical entity called Alpha-1062, an acetylcholine esterase inhibitor to treat Alzheimer's disease (completed human trials). The company has also developed Alpha-602 for treating ALS.
- Sep 2024Post IPO$4.5M
- Jan 2024Post IPO$3.7M
- Dec 2023Post IPO$1.8M
- Nov 2023Post IPO$4.7M
#4
Public · Vancouver, British Columbia · founded 2016 · 11 employees$21.6Mraised▾
Developer of therapeutics for the treatment of nerve damage. It has developed technology that targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that inhibits nerve regeneration. The company is developing candidate NVG-291, an inhibitor of the PTPσ receptor and being clinically tested for spinal cord injury.
- Oct 2022Grant (prize money)$1.5M
- Jul 2022Post IPO$15.2M
- Dec 2021Post IPO$651.8K
- Aug 2021Post IPO$263.7K
#5
Deadpooled · Vancouver, British Columbia · founded 1998$126Mraised▾
Neuromed Pharmaceuticals provides calcium channel blockers for pain therapies. It focuses on the development of N-type and T-type calcium channel blockers for the treatment of chronic pain. The company’s products include OROS Hydromorphone, a Phase 3 extended release formulation of hydromorphone; oral drug candidates to block N-type calcium channels; and T-type calcium channel blockers for treating pain, epilepsy, and hypertension. Neuromed Pharmaceuticals was formerly known as Neuromed Technologie and changed its name to Neuromed Pharmaceuticals in March 2006.
- Aug 2007Series E$53.3M
- Mar 2006Series D$25M
- Nov 2003Series C$32M
#6
Public · Burnaby, British Columbia · founded 2000 · 19 employees$85.7Mraised▾
Developer of small molecule drugs against rare channelopathies. They have built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. The company has a proprietary discovery platform, Extreme Genetics which involves the study of families where individuals exhibit inherited severe traits or phenotypes. With Teva, they are developing TV-45070, a topical Sodium Channel Inhibitor for the treatment of pain.
- Sep 2006Series C$5M
- Apr 2006Series C$31M
- 2004Series C$4.7M
- Apr 2001Series C$45M
#7
Public · Kelowna, British Columbia · founded 2020 · 11 employees$3.6Mraised▾
Developer of therapeutic solutions for treating neuropsychiatric disorders & pain. The company has developed PFN program candidate TRP-8802 with the indication of fibromyalgia that helps in treating chronic pain conditions, CNS disorders, and more. It also provides Razoxane TRP-1001 drug candidate for soft tissue sarcomas. It increases the efficacy of natural blood-brain barrier penetration, reduces the risk of abuse and addiction.
- Nov 2023Post IPO$2M
- Oct 2023Post IPO—
- Apr 2023Post IPO$1.6M
- Feb 2022Post IPO—
#8
Deadpooled · Surrey, British Columbia · founded 2007 · 11 employees$48.4Mraised▾
Methylation Sciences (MSI) is developing small molecules for Major Depressive Disorder (MDD). Its lead product MSI-195 is based on S-adenosyl methionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. The candidate is currently in phase 2 trials for MDD. It claims to have a broad intellectual property portfolio and pipeline of candidates.
- Oct 2016Series B$30M
- Mar 2015Series A$19.8K
- Sep 2011Series A$18.4M
#9
Acquired · Vancouver, British Columbia · founded 2006 · 4 employees$77.3Kraised▾
Entheon Biomedical is a developer of psychedelic medicines for addiction disorders. The company has developed serotonin receptor modulating psychedelic molecules and patented psilocybin-based and DMT-based formulations to treat substance abuse disorders.
- Jan 2025Post IPO$346K
- Apr 2024Post IPO$147.5K
- Jun 2020Seed$77.3K
#10
Early Stage · Vancouver, British Columbia · founded 2001 · 23 employees$20.4Mraised▾
Evasc Medical is developing a solution for endovascular repair of cerebral aneurysms. The company is developing eCLIPs Aneurysm Remodeling System, which is designed to treat most of the cerebral aneurysms, including challenging wide-neck bifurcations. The first use of eCLIPs in a human patient was performed in 2013 under Health Canada’s Special Access Program. It received CE Mark approval in 2014, and FDA HUD designation in December 2015.
#11
Acquired · Vancouver, British Columbia · founded 2021 · 11 employees$2.4Mraised▾
Manufacturer of psychedelic therapy drug for addiction
- Nov 2021Seed$2.4M
#12
Public · Kelowna, British Columbia · founded 2010$1.9Mraised▾
Manufacturer of drugs for neurological disorders. The company has developed medications for neuropsychiatric disorders. It can be used to treat major depressive disorder, chronics inflammation, and other neuroimmunological disorder.
- Nov 2021Grant (prize money)—
- Jan 2021Seed$1.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.